All In Biotech

NDA 009190 · Guerbet

Lipiodol

Ethiodized Oil · Intralymphatic, Intrauterine · Radiographic Contrast Agent

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 5, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1954

Mar 31, 1954

Approved uses

2

Original approval plus efficacy supplements

Registered trials

119

33 Phase 3, 20 recruiting

FAERS reports

1,298

1,258 serious, 154 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FOR INTRALYMPHATIC, INTRAUTERINE AND SELECTIVE HEPATIC INTRA-ARTERIAL USE ONLY Pulmonary and cerebral embolism can result from inadvertent intravascular injection or intravasation of Lipiodol. Inject Lipiodol slowly with radiologic monitoring; do not exceed recommended dose ( 5.1 ). WARNING: FOR INTRALYMPHATIC, INTRAUTERINE AND SELECTIVE HEPATIC INTRA-ARTERIAL USE ONLY See Full Prescribing Information for complete Boxed Warning Pulmonary and cerebral embolism can result from inadvertent intravascular injection or intravasation of Lipiodol. Inject Lipiodol slowly with radiologic monitoring; do not exceed recommended dose ( 5.1 ).

What it is approved for

From the label in effect Dec 16, 2025.

Lipiodol is an oil-based radio-opaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC) Lipiodol is an oil-based radiopaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)

Mechanism: Lipiodol opacifies vessels and body structures in the path of the flow of the contrast medium, permitting visualization of the internal structures.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 4, 2014 Supplement 24 · Efficacy LabelLetter
  • Mar 31, 1954 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • LIPIODOL · ETHIODIZED OIL EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML) · OIL, INTRALYMPHATIC, INTRAUTERINE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethiodized Oil" as an intervention, any sponsor and status, largest first.

All 119 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use in unapproved indication294
  • off label use170
  • liver abscess73
  • pyrexia59
  • pulmonary embolism49
  • product use issue43
  • aspartate aminotransferase increased40
  • pancytopenia36
  • alanine aminotransferase increased35
  • disease progression33
  • overdose31
  • hepatic artery stenosis30

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20066
20073
20083
20098
20107
201129
201226
201325
201425
201564
201682
2017109
2018123
201997
202076
202164
202267
202386
2024144
2025109
2026143

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 299 on PubMed

Sponsor: Guerbet

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.